Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2018 Mar 29.

Published in final edited form as: Pharmacogenomics J. 2012 Feb 28;13(3):242–250. doi: 10.1038/tpj.2012.5

Association between Genotype of Markers in CRHR1 and Pulmonary Function for Montelukast Treatment. Mean percent changes in percent predicted FEV1 (±SE) were calculated between week 16 and visit 1 (randomization) in participants taking montelukast by genotype for rs739645(□); rs1876831 ( ); rs1876829 ( ); and rs1876828 (■). MM refers to homozygous for the major alleles; mM refers to heterozygotes; and mm refers to homozygotes for the minor alleles.

Inline graphic — Association between Genotype of Markers in CRHR1 and Pulmonary Function for Montelukast Treatment. Mean percent changes in percent predicted FEV1 (±SE) were calculated between week 16 and visit 1 (randomization) in participants taking montelukast by genotype for rs739645(□); rs1876831 ( ); rs1876829 ( ); and rs1876828 (■). MM refers to homozygous for the major alleles; mM refers to heterozygotes; and mm refers to homozygotes for the minor alleles.